Skip to main content
Premium Trial:

Request an Annual Quote

Orchid to Remain Listed on Nasdaq Until at Least June 24

NEW YORK, March 28 - Nasdaq will continue to list Orchid Biosciences' common stock through June 24, the company said today.


Orchid received a delisting warning notice from Nasdaq on Jan. 3 after trading below $1.00, the minimum bid price required for continued listing on the exchange, for several months.The company appealed and a hearing before a Nasdaq listing qualifications panel was held in February.


Last week, Orchid said that Nasdaq had given it permission to go ahead with a private financing of $16 million without seeking shareholders' approval, which the company is hoping to close within the next few days.


Orchid is also seeking shareholder approval for a reverse stock split at a special shareholder meeting scheduled for April 15.


For further information, see the company statement.


The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.